There was a notable gap in effectiveness between metered-dose and dry-powder formulations of single-inhaler triple therapy for chronic obstructive pulmonary disease (COPD), according to real-world ...

The Efficacy and Safety of Triple Therapy in Obstructive Lung Disease (ETHOS) and Informing the Pathway of Chronic ...

Researchers conducted an observational study using real‑world data to compare the effectiveness and safety of initiating three fixed‑dose long‑acting muscarinic antagonist (LAMA)-long‑acting beta‑2 ...

People living with chronic obstructive pulmonary disease (COPD) typically rely on maintenance inhalers to manage their daily symptoms. They may also take rescue inhalers for sudden breathing ...

New long-acting muscarinic antagonist-long-acting beta agonist users had a decreased risk for a first moderate/severe COPD ...

Please provide your email address to receive an email when new articles are posted on . Several clinicians expressed concern about inhaler costs for those with COPD in January. AstraZeneca, Boehringer ...

Those receiving budesonide-glycopyrrolate-formoterol compared with fluticasone-umeclidinium-vilanterol had a higher risk for a first moderate COPD exacerbation. William B. Feldman, MD, MPH, from ...

Add Yahoo as a preferred source to see more of our stories on Google. Inhalers that provide fast-acting treatment for people with certain respiratory conditions are contributing to greenhouse gas ...

New research from UCLA Health suggests that certain inhalers used to treat chronic obstructive pulmonary disease (COPD) are not only less harmful to the environment but can also lead to slightly ...

The FDA approved United Kingdom-based GlaxoSmithKline’s Trelegy Ellipta, a once-daily inhaler that contains three medicines for chronic obstructive pulmonary disease. The inhaler, developed with the ...